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Abstract
Ovarian cancer is the most deadly gynecological cancer. The high rate of mortality is due to the large tumor burden with
extensive metastatic lesion of the abdominal cavity. Despite initial chemosensitivity and improved surgical procedures,
abdominal recurrence remains an issue and results in patients’ poor prognosis. Transcriptomic and genetic studies have
revealed significant genome pathologies in the primary tumors and yielded important information regarding
carcinogenesis. There are, however, few studies on genetic alterations and their consequences in peritoneal metastatic
tumors when compared to their matched ovarian primary tumors. We used high-density SNP arrays to investigate copy
number variations in matched primary and metastatic ovarian cancer from 9 patients. Here we show that copy number
variations acquired by ovarian tumors are significantly different between matched primary and metastatic tumors and these
are likely due to different functional requirements. We show that these copy number variations clearly differentially affect
specific pathways including the JAK/STAT and cytokine signaling pathways. While many have shown complex involvement
of cytokines in the ovarian cancer environment we provide evidence that ovarian tumors have specific copy number
variation differences in many of these genes.
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Introduction
Epithelial Ovarian carcinoma (EOC) is the sixth most common
malignancy in woman and the leading cause of death from
gynecological cancer in the world [1]. The poor overall survival
(20 to 30% at 5 years) is due to the large tumor burden with
extensive metastatic lesions of the peritoneal cavity. Despite initial
chemosensitivity and improved surgical procedures abdominal
recurrence remain an issue and results in patients’ poor prognosis.
Therefore it is critical to understand the molecular pathways
underlying peritoneal metastasis in order to define new therapeutic
strategies [2].
Efforts have been made to delineate gene expression
signatures for prognostic predictions as well as chemotherapeutic
responses [3–6]. These studies have attempted to provide gene
predictors on disease outcome, however, the robustness and
reproducibility of these genes lists across different patient
populations have not yet been clearly established or translated
to clinical practice [7].
The complex cytogenetic alterations of ovarian carcinoma and
the lack of high-resolution technologies have hindered the
identification of specific genes involved in the metastatic process.
Using low-resolution platforms, wide-spread copy number
changes of 7 amplicons (CCNE1, Notch3, HBXAP/Rsf-1,
AKT2, PIK3CA and chr12p13) in high-grade tumors were
identified while a relatively flat and quiet chromosomal landscape
was found in low-grade tumors [8]. Recently, analysis performed
by the TCGA and other groups with much higher resolution
platforms have shown numerous and frequent micro-deletions
and amplifications across the genome, with genes CCNE1, RB1,
MYC, MECOM and FGFR1 highlighted among others [9,10].
While recent studies of high number of patients have led to the
precise characterization of the genetic alterations in serous
ovarian carcinoma [11], there has been little effort, to our
knowledge, to understand the dynamics of large scale genetic
modification differences between the primary lesions and the
peritoneal metastasis. In a study on loss of heterozygosity,
Khalique and colleagues compared primary and metastatic
ovarian tumors using 22 microsatellite markers in 22 patient
samples [12]. Despite the low resolution resulting in a lack of
functional analysis their overall findings on tumor progression
agree with ours presented here.
Therefore we hypothesize that a prospective collection of
homogenous primary and metastatic lesions from patients with
advanced ovarian carcinoma would allow a comprehensive view of
genetic modification and have the potential to define important
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papillary ovarian carcinoma.
Results
We identified 9 patients with matched ovarian and peritoneal
metastatic tumors (Table 1). All primary tumors were grade 3
papillary serous tumors stage IIIc, and all patients had primary
upfront debulking surgery. One biopsy was performed from the
primary tumor, and one biopsy was performed from a peritoneal
metastatic lesion without the underlying peritoneal stroma.
We used the Affymetrix SNP 6.0 chip to detect regions with
significant copy number variations (CNV) with respect to either a
HapMap control set or the matched primary tumors. For
validation, we selected 14 regions for quantitative-PCR validation
of peritoneal metastasis versus primary tumor copy number. The
regions included 3 controls shown to not be within CNVs in the
patient’s studied here, and an additional 11 regions (Table S1)
within 5 genes showing CNV among the patients. We had
sufficient DNA from 16 of the 18 tumors investigated by array
(DNA from patient OV07-3 was insufficient) for qPCR validation.
Our results (Table S2) show that 83% of regions agreed between
the qPCR and Array data. We detected 7.5% false negatives
(missed CNVs) and 10% false positives. These data are
conservative in assuming qPCR is always correct. The results
here agree favorably with previous findings [13,14] for the
frequency of qPCR agreement with data from Affymetrix SNP
6.0 data analyzed with PARTEK software.
Primary and metastatic comparison to normal
We first compared genomic DNA from primary and metastatic
lesions with a dataset of normal tissues provided by the HapMap
project. This should yield cancer specific amplifications and
deletions when compared to normal tissue (Figure 1). Only
regions amplified or deleted in at least 3 samples were
documented. In individual patients, segments of amplification
and deletion could be quite long, however, when compared
among multiple patients the boundaries of CNVs were tightened
making the average CNV segment ,200 kb. There were 8681
segments, spanning 2.1 Gb of sequence, detected as CNVs in at
least 3 patients in the primary tumors (Table S3). 4176 were
amplifications spanning 957 Mb with average segment size of
230 kb. 4257 were deletions spanning 1152 Mb with average
segment size of 270 kb. On average an individual patient had
2445 amplified segments spanning 530 Mb and 2412 deleted
segments spanning 651 Mb. There were 5878 segments detected
as CNVs in at least 3 patients in the peritoneal metastasis samples
(Table S4). 2445 were amplifications spanning 364 Mb with
average segment size of 149 kb. 3366 were deletions spanning
621 Mb with average segment size of 184 kb. On average an
individual patient had 1289 amplified segments spanning 170 Mb
and 1542 deleted segments spanning 290 Mb in the peritoneal
metastasis. Encouragingly, the most frequent amplifications and
deletions agreed with previous published studies [10]. These
included amplifications in 3q, 6p, 8q, 12p and 20, and deletions
in 4q, 5q, 6q, 8p, 16p, 17, 22, and X among others (Table S3,
Table S4). Genes in CNVs, both shared and tumor specific, were
documented in Table S5.
While our data agrees well with previous ovarian CNV studies
[10], little has been done to characterize functional pathways
affected by these consistently amplified and deleted regions.
Functional analysis by DAVID [15] of genes within regions
amplified in both primary and metastatic regions revealed
enrichment of genes involved in the JAK/STAT signaling
pathway (29 genes, Benjamini-Hochberg (BH) score 0.0067) and
Cytokine-Cytokine Receptor pathway (38 genes, BH score 0.06)
among others. Deletions were enriched for genes involved in
Apoptosis (28 genes, BH 0.092), MAPK signaling (66 genes, BH
score 0.099) among others. Deleted apoptosis related genes
included p53, ATM, Bcl-2, NF-kB, IKK, CASP3 and CASP6
among others. It is clear from our analysis that the metastasis has
fewer specific copy number changes (176 fewer specific amplifi-
cations and 36fewer deletions on average) when compared with
the primary tumor (Table S5). A similar trend was observed in
breast cancer where primary tumors had on average 20% more
changes than their metastatic counterparts [16]. This may be due
to a microenvironment pressuring the metastatic tumor to
maintain certain pathways. The disproportionate number of
primary tumor specific amplifications may suggest a concerted
requirement, post-metastatic spread, to increase gene copy
number in specific genes for tumor maintenance. It might also
suggest that the metastatic event occurs quite early in the
occurrence of the disease with the metastatic clones being less
prone to amplifications and deletions in their new microenviron-
ment and this is discussed below.
For corroboration of pathways identified in the CNV analysis,
we searched gene expression data of the same samples (Malek
et al., in preparation) for genes differentially expressed between
primary and metastatic tumors. Functional analysis of gene
expression data also revealed enrichment of differentially ex-
pressed genes in the cytokine/receptor interaction pathway and in
the JAK-STAT signaling pathway. These findings are not
unexpected as the underlying CNVs likely affect gene expression.
To our knowledge the identification of significant enrichment of
JAK-STAT signaling and cytokine/receptor genes within ovarian
CNVs is novel. Given that both primary and metastatic tumor
CNVs showed highly significant enrichment of these genes, and
because gene expression data showed genes in these pathways to
be differentially expressed between primary and metastatic
tumors, we chose to focus our functional analysis on these
pathways. Groups of amplifications and deletions (shared by both
primary and metastatic, primary specific, metastatic specific, and
peritoneum compared directly to primary) were mapped to the
JAK/STAT signaling pathway (Table 2). It is clear from this
analysis that multiple genes in the JAK/STAT pathway are
affected by CNVs and indeed genes within the same category (for
example Interleukins) may be both amplified and deleted in the
same comparison. These amplifications and deletions in the same
categories are likely coordinated. For example, 5 patients had
deletions in the TYK2 gene (a JAK protein), yet 3 of these
(patients OV07-1, OV07-4 and OV08-3) were the only 3 patients
amplified in the JAK2 gene. This may be an indication of
constraints on the balancing of loss and gains in this pathway.
Dense copy number variations from multiple comparisons were
Table 1. Patient Information used in this study.
Age 61 +/2 7
Histology (9 patients) Papillary-serous adenocarcinoma
Grade (9 patients) 3
Stage
IIIC 8
IV (pleural) 1 (patient 07c3714)
Adjuvant treatment Carboplatin and taxol (6 cycles)
doi:10.1371/journal.pone.0028561.t001
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gene families were analyzed with more detail.
We documented all cytokine/chemokine signaling pathway
related genes in CNVs and observed trends specific to primary and
metastatic tumors (Table S6). Specifically, large numbers of
cytokines of the CC subfamily (and corresponding receptors) were
specifically deleted in the primary tumor and not in the metastasis
(Figure 2, Table 3). This is of interest as it has been shown
previously that primary tumors are deficient in CC chemokine
receptor [17]. For example we observed a deletion in the CCL2
(LOH in 17q) gene which has been observed to delete in 70% of
primary ovarian tumors [18] however this extremely common
primary tumor deletion was not observed in the peritoneal
metastasis. This lack of deletion was irrespective of age of the
metastasis (discussed below). The fact that the metastasis does not
delete these genes shows a clear difference between the metastasis
and the primary tumors and may likely be due to functional
constraints required for the spread and maintenance in a different
microenvironment. The role of the CC chemokine family in
cancer progression has been widely described in the literature [19].
We observed primary tumor deletion in multiple CC chemokine
genes (ligand or receptors) in all but one patient (OV08-2)
suggesting this pathway is altered with high frequency (Table 3).
Interestingly, patient OV08-2 was the only patient with refractory
cancer in our cohort. Whether the complete absence of CC
chemokine deletions in this patient’s primary tumor is related to
this refractory state will require further investigation of similar
patients.
Likewise, large numbers of the CXC chemokine subfamily were
amplified in primary but not metastatic lesions (Table S6),
however this showed much more variability than the CC
subfamily. Between 3 and 4 patients were amplified while between
2 to 3 were deleted in the same genes. In the matched metastasis
only 1 to 2 patients showed CNVs in these genes and were not
reported. This lack of consistency for the CXC subfamily CNVs
results in failing to meet the threshold set for reporting. CXCL12,
which stimulates ovarian cancer cell invasion, was amplified and
has been shown to be expressed in ovarian cancer but not normal
ovaries or ovarian surface epithelium [20]. However, the lack of
consistency in the CXC subfamily CNVs may indicate these are
either secondary genes to a more critical pathway or that there
may be coordination of amplification and deletion between these
and other genes.
We further searched gene expression data of the same samples
(Malek et al., in preparation) for genes contained within a CNV
and that had significant gene expression differences between
primary and metastatic tumors. Of 9 differentially expressed
chemokine pathway genes, 6 had the expected gene expression
trend based on the CNV. Specifically, CXCR6, CCR2, CCR4,
IL2Ra were both deleted and had lower gene expression in the
primary versus metastatic tumors. Conversely, CCL28 and
VEGF-A were both amplified and had higher gene expression in
the primary versus metastatic tumors.
Matched Metastatic/Primary Tumor CNV analysis
While both primary and metastatic lesion CNVs showed
significant overlap with previous studies, large regions were
different between the two types (Figure 3). These differences
may indicate selective pressure based on different microenviron-
ments, selective pressure based on the requirement of metastasiz-
ing, or simply the difference between two clonal populations
within the primary tumor prior to the event of metastasis. These
differences were highlighted even more when matched primary
and metastatic lesions were directly compared to each other for all
9 patients to reveal possible metastatic specific trends (Figure 3).
There were 2355 segments amplified and 2734 segments deleted
in at least 3 patients in the peritoneal metastasis compared to the
primary tumor (Table S7). These spanned 562 Mb with average
Figure 1. Ovarian tumor copy numbers in genomic DNA compared to a normal baseline. A) Primary tumors. B) Peritoneal metastasis.
Amplifications are in red and deletions in blue.
doi:10.1371/journal.pone.0028561.g001
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of 216 kb respectively.
We observed significant differences among patients in the
number of shared CNVs between matched primary and metastatic
lesions (Figure 4). This information may allow a better
understanding of tumor progression timelines, as more recently
metastasized tumors are likely to share more CNVs in common.
Likewise early metastatic events would allow longer divergence
time between primary and metastatic tumors and would result in
large numbers of CNV differences. Three patients showed very
few differences between the primary and peritoneal metastasis and
large numbers of shared differences to the HapMap baseline
suggesting that the metastatic event was recent (late in tumor
progression). Four patients had large numbers of differences
between the primary and metastatic tumors (early metastasis) with
the metastatic tumors remaining closer to the normal copy
number levels. Two patients had more intermediate levels of
differences with one case (OV08-2) showing fewer differences to
the baseline than the metastatic tumor. Whether tumor progres-
sion is specific to the patient, or simply the metastatic lesions that
were randomly biopsied remains to be investigated. These
significant differences in tumor progression timelines may be
critical to better understanding the role of any given difference
between primary and metastatic tumors.
With the recent comprehensive genomic analysis results
published by the TCGA group on ovarian primary tumors we
attempted to identify differences and similarities between
metastatic tumors studied here and the TCGA findings. In their
analysis they observed regular amplifications of certain genes that
are already chemotherapeutic targets and suggested these for
possible treatment options. As expected, many of our primary
tumors contained amplifications of the same genes, however,
many of these genes were not amplified in their matching
peritoneal metastasis (Figure 5). Indeed, among the 9 patients’
primary tumors we observed 64 amplification events in 13 genes
identified by the TCGA as regularly amplified. Only 6 (9%) of
the events were as highly amplified in the matched metastases
and altogether only 15 (23%) had any form of amplification in the
metastases. This observation is important as the typical
complications of ovarian cancer result from peritoneal recurrence
after surgical removal of the primary tumor. These results suggest
that chemotherapy treatment recommendations made only on
amplifications observed in the primary tumor may not be
effective due to the residual metastatic disease not sharing the
same amplifications.
Importantly, by using matched primary and metastatic lesions
we could detect regions that had continued to change after the
metastatic spread. These can be identified as amplifications and
deletions that are shared between both primary and metastatic
tumors when compared to a normal baseline and are further
annotated as amplifications and deletions when the matched
tumors are compared to each other (Table S6). For example, the
chromosome 8q region is amplified in both primary and metastatic
tumors (Figure 1a, Figure 1b). However, because the primary
tumor is further amplified over matched metastatic tumors in at
least 3 patients, the region is documented as a peritoneal
metastatic deletion when the primary is used as a baseline
(Figure 3). For consistency, we focused our analysis on the
Cytokine signaling pathway (Table S6). In the case of shared
amplifications that further amplify in the primary tumor we
observed genes such as EGFR, GHR, IL7 and TNFR ligands
among others. Genes that were amplified in both and further
amplified in the metastatic tumor were almost exclusively IFNA
related and were in the IFNA cluster on Chromosome 9p (Table
S6). Indeed we observed continuing amplification in the metastasis
for IFNA 1,2,4–8,10,13,14,16, 17 and 21. Shared deletions
contained genes that continued to amplify in the peritoneum
and these included FIGF (VEGF-D), IL 3,4,5,6ST,11, and 13
among others.
Discussion
To our knowledge this is the first published report of
comparison of genome-wide CNVs between matched primary
and metastases in ovarian cancer. All in all our data agree well
with previous CNV analysis of ovarian primary tumors and this
supports the new findings in the matched peritoneal metastasis
[9,11]. Analysis of CNV regions shared among tumor types
showed affected genes involved in numerous cancer pathways
including the amplifications in the JAK/STAT pathway and
deletions in the Apoptosis pathways. The role of JAK/STAT
pathway has already been suggested in ovarian cancer. Indeed
Colomiere et al. suggested a cross talk between EGFR and
Il6Receptor in the EMT transition in ovarian carcinoma. They
demonstrated the role of STAT3 in IL6 mediated migration of the
cancer cells through EMT [21]. Seo et al. showed that LPA, which
Table 2. Copy Number Variations in the KEGG JAK/STAT
pathway gene families.
Shared
Peri
Specific
Prim
Specific
Peri V
Prim
Gene Symbol Amp Del Amp Del Amp Del Amp Del
EPO XXX X X X
IFN/IL10 XX X X
IL2/3 XX X XX
IL6 XX X X XX
CytokineR XX X X XX
JAK XX X XX
Cbl
STAM X
SHP1 XX X
SHP2 XX X
GRB
SOS XX X
PI3K XX X X X
AKT XX X X
STAT XX X
PIAS XX X X X
SOCS XX X X
IFNalpha/P48
CBP XX
Pim-1
CIS XX
c-Myc XX
CycD XX
BclXL XX
Spred XX X
Sprouty XX
doi:10.1371/journal.pone.0028561.t002
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ovarian cancer, also activates STAT3 through secretion of IL6 and
IL8 [22]. Meinhold-Heerlein et al. demonstrated that G2/G3
cancers were characterized by the expression of genes associated
with the cell cycle and by STAT-1-, STAT-3/JAK-1/2-induced
gene expression [23]. In this study we have observed that the role
of JAK/STAT pathway changes may begin very early in tumor
progression as many CNVs in this pathway were shared between
primary and metastatic tumors. This would suggest that this
pathway might be as important as other very early genetic
abnormalities in tumor progression such as TP53 mutations.
Changes in the pathway may then be specifically selected for by
metastatic environmental requirements.
We further identified pathways that were affected in primary or
metastatic tumors specifically. We observed primary tumor
deletions in multiple CC chemokine genes (ligand or receptors)
in all but one patient (OV08-2) suggesting this pathway is altered
with high frequency. While we realize the number of cases is too
small to draw firm conclusions, the relative homogeneity of
ovarian cancer CNVs (our data as well as Bowtell group) might
advocate for the possibility of only a few pathways being required
in the change toward metastasis. Genome-wide CNV analysis on a
greater number of patients will allow us to determine if indeed the
pathways to metastasis are few and therefore consistent.
Interestingly, patient OV08-2 was the only patient with refractory
cancer in our cohort. Whether the complete absence of CC
chemokine deletions in the primary tumor is related to this
refractory state will require further investigation of a higher
number of such patients. While the approach of using matched
primary and metastatic lesions to study ovarian cancer genome-
wide CNVs is unique in this study, a similar study in breast cancer
has been reported [16]. Similar trends in the scale of differences
between primary tumors and metastases were observed. By using
the SNP6.0 array we increased resolution significantly allowing
more refined determination of CNV segment boundaries. This
increase in resolution highlighted the numerous differences
between primary tumors and their metastases.
It is clear from our study that metastatic tumors are different
from their ovarian primary source. Microenvironment pressures as
well as the requirement for migration may select for copy number
variations in these different pathways. The most frequently
differentiating pathway we observed among primary and meta-
static tumors was in the cytokine family of genes. This finding was
corroborated by similar trends in gene expression data. The
frequent involvement of cytokines in immune response and
migration in cancer makes this an interesting finding. Indeed the
role of immune infiltration has been recently described in different
tumors including colon cancer and ovarian cancer [24–26]. More
targeted studies are required in order to understand the differential
immune environment in the primary and metastatic lesions. The
understanding of the subtle microenvironment differences might
allow the modulation of the immune response in order to avoid
peritoneal recurrences [26].
Recently the TCGA group published the results of their
comprehensive analysis of 489 patients with high-grade serous
ovarian adenocarcinoma [10]. While the information on primary
tumors from the TCGA is critical, we have shown that many
targets of chemotherapy that are regularly amplified in both the
TCGA and our samples are not amplified in matched metastatic
tumors. Treatment decisions will need to carefully consider the
genomic differences between primary and residual/metastatic
tumors prior to chemotherapeutic recommendation.
Our study highlights the benefit and importance of performing
paired analysis of primary tumors and their metastatic lesions in
ovarian cancer. While comparison of primary and metastasis as
groups provided insight into cancer development, the matched
analysis allowed more specific detection of consistent differences.
Indeed advanced disease allows access to not only the primary but
also the different metastatic sites. It has been clearly demonstrated
that the patients’ prognosis relies on tumor residue; therefore it is
critical to understand the biology of the metastatic lesions in order
to design appropriate new therapeutic approaches. The results
presented here should be a step in that direction.
Figure 2. The CC chemokine subfamily deletions in primary but
not metastatic tumors. Large numbers of CC subfamily chemokines
and there receptors were deleted (starred red) in the primary tumor but
not in matched peritoneal metastasis.
doi:10.1371/journal.pone.0028561.g002
Copy Number Variation in Ovarian Cancer
PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e28561T
a
b
l
e
3
.
C
C
f
a
m
i
l
y
C
y
t
o
k
i
n
e
s
a
n
d
R
e
c
e
p
t
o
r
s
d
e
l
e
t
e
d
i
n
p
r
i
m
a
r
y
b
u
t
n
o
t
m
e
t
a
s
t
a
t
i
c
t
u
m
o
r
s
.
C
h
r
S
e
g
S
t
a
r
t
S
e
g
E
n
d
b
a
n
d
G
e
n
e
O
V
0
6
-
1
O
V
0
7
-
1
O
V
0
7
-
2
O
V
0
7
-
3
O
V
0
7
-
4
O
V
0
7
-
5
O
V
0
8
-
1
O
V
0
8
-
2
O
V
0
8
-
3
C
C
L
D
e
l
e
t
i
o
n
s
2
2
2
8
2
8
2
5
7
6
2
2
8
8
6
5
5
9
6
2
q
3
6
.
3
C
C
L
2
0
X
X
X
X
1
7
3
0
5
3
4
9
9
2
3
3
4
1
9
5
8
1
1
7
q
1
1
.
2
-
1
7
q
1
2
C
C
L
1
,
C
C
L
1
1
,
C
C
L
1
3
,
C
C
L
2
,
C
C
L
7
,
C
C
L
8
X
X
X
X
1
7
3
3
4
1
9
5
8
1
3
4
4
3
6
1
2
9
1
7
q
1
2
C
C
L
1
4
,
C
C
L
1
4
-
C
C
L
1
5
,
C
C
L
1
5
,
C
C
L
1
6
,
C
C
L
1
8
,
C
C
L
2
3
,
C
C
L
3
,
C
C
L
4
,
C
C
L
5
X
X
X
X
1
7
3
4
4
3
6
9
1
8
3
4
4
7
5
9
1
3
1
7
q
1
2
C
C
L
4
X
X
X
X
1
7
3
4
4
7
5
9
1
3
3
4
5
3
9
4
9
7
1
7
q
1
2
C
C
L
3
L
1
,
C
C
L
3
L
3
,
C
C
L
4
L
1
X
X
X
X
X
1
7
3
4
5
3
9
4
9
7
3
4
7
2
2
9
7
6
1
7
q
1
2
C
C
L
3
L
1
,
C
C
L
3
L
3
,
C
C
L
4
L
1
,
C
C
L
4
L
2
X
X
X
X
X
1
9
8
0
2
4
7
1
8
8
3
3
1
6
0
9
1
9
p
1
3
.
2
C
C
L
2
5
X
X
X
X
X
C
C
R
D
e
l
e
t
i
o
n
s
3
3
2
9
5
5
2
0
8
3
3
1
2
4
3
2
8
3
p
2
2
.
3
C
C
R
4
X
X
X
X
3
3
8
9
9
7
4
0
2
3
9
5
0
7
6
5
3
3
p
2
2
.
2
-
3
p
2
2
.
1
C
C
R
8
X
X
X
3
4
5
3
2
5
0
6
6
4
7
0
5
2
3
1
4
3
p
2
1
.
3
1
C
C
R
1
,
C
C
R
2
,
C
C
R
3
,
C
C
R
5
,
C
C
R
9
,
C
C
R
L
2
X
X
X
6
1
6
6
7
7
0
2
3
6
1
6
9
5
0
3
0
2
5
6
q
2
7
C
C
R
6
X
X
X
X
X
1
7
4
0
3
0
5
1
3
3
4
1
2
0
3
4
3
5
1
7
q
2
1
.
2
-
1
7
q
2
1
.
3
1
C
C
R
1
0
X
X
X
X
X
C
h
r
:
c
h
r
o
m
o
s
o
m
e
,
s
e
g
s
t
a
r
t
/
e
n
d
:
s
e
g
m
e
n
t
s
t
a
r
t
a
n
d
e
n
d
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
2
8
5
6
1
.
t
0
0
3
Copy Number Variation in Ovarian Cancer
PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e28561Materials and Methods
Ethics Statement
All the samples were collected in the department of Gynecologic
Oncology at the institut Claudius Regaud (DQ, AR). The project
was reviewed and approved by the institution’s Human research
Ethics Committee. All patients included in the study gave
informed written consent prior to surgery. 9 patients with advance
Stage III or IV papillary serous ovarian adenocarcinoma were
prospectively enrolled in this study at the time of primary surgery
before any treatment was given. The patients had a biopsy of the
primary lesion as well as a peritoneal metastasis outside of the
pelvis. In order to ensure very little contamination by the stromal
components the biopsies specifically took the tumoral nodules
without the underlying peritoneal elements. All biopsies were
immediately liquid nitrogen snap frozen. A representative
haematoxylin and eosin stained section was assessed and samples
with 80% epithelial cells and less than 20% of necrosis (criteria
used by the TCGA group [10]) were used for DNA and RNA
extraction from the whole tissue.
RNA and DNA isolation
DNA and RNA were isolated using QIA-cube technology as per
the manufacturer instructions.
Affymetrix SNP Array 6.0 Processing
We used the Affymetrix Genome-Wide SNP Array 6.0 for the
genomic analysis for the detection of copy number changes in this
study. The workflow of Affymetrix Genome-Wide SNP Array 6.0
strictly followed the cytogenetic protocol from the manufacturer.
250 ng of total genomic DNA have been analyzed. The normal
controls will be obtained from the 270 HapMap samples provided
by Affymetrix.
Quantitative-PCR Validation of Copy Number Variations
We selected a subset of regions identified as varying in copy
number between primary tumor and peritoneal metastasis. As
endogenous controls, we selected 3 gene regions that were
shown by array analysis to not be amplified or deleted in our
samples. Primers were designed using Primer3Plus on the hg19
version of the human genome (Table S1). For each primer pair
quantitative PCR (QPCR) was conducted in triplicate on an
Applied Biosystems 9700 Real-Time PCR machine using a
10 ul reaction of KAPA SYBR FAST Universal 26 qPCR
Master Mix (Kapa Biosystems), 1.25 pmol each primer and
5 ng of genomic DNA and cycled according to the manufac-
turers recommended protocol. Analysis was conducted with
the Applied Biosystems Relative Quantitation Manager
software to calculate delta-delta Ct. Sample were normalized
Figure 3. Peritoneal metastasis copy number variation compared to matched ovarian primary tumors. Amplifications are in red and
deletions in blue. This comparison highlights differences between matched patient samples and helps identify regions of ongoing copy number
change.
doi:10.1371/journal.pone.0028561.g003
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PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28561Figure 4. Lengths of copy number variations shared among tumor types differ among patients. Lengths of shared copy number
variations between peritoneal (perit.) metastasis and matched primary (prim.) tumors were plotted for each patient. Peritoneal metastases that do
not differ much from their primary tumors tend to have large numbers of differences to the HapMap (normal) baseline and likely metastasized only
recently. We only observed one patient (OV08-2 with fewer primary tumor CNVs than the peritoneal metastasis). These data suggest groups of early,
mid and late metastatic groups separated by amount of shared CNVs between the tumor types.
doi:10.1371/journal.pone.0028561.g004
Figure 5. Genes identified as frequently amplified in primary ovarian tumors by the TCGA. Genes frequently amplified in primary tumors
were suggested by the TCGA as potential chemotherapeutic targets. While primary tumors we studied agreed well with the TCGA findings, we find
that metastatic, and likely residual, tumors do not regularly share the same amplifications. This should be considered prior to chemotherapeutic
recommendations. Amp: amplified, Lamp: low-level amplification (not as amplified as in primary tumor) Nrm: no CNV with respect to HapMap
baseline, Del: deletion.
doi:10.1371/journal.pone.0028561.g005
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were checked using the primary tumor samples as baseline
reference.
Data analysis
SNP arrays (Copy Number Variation analysis). Data
from the SNP6.0 arrays were analyzed using the PARTEK
Genomics Suite software with recommended normalization
settings. Each sample was compared to a HapMap distributed
baseline to identify amplified and deleted regions using as
segmentation algorithm within PARTEK. Segments showing
copy number variation were only reported if they occurred in at
least 3 patients with an individual patient False Discovery Rate
(FDR) no greater than 20%.
Functional Analysis. Gene lists from both the gene
expression and copy number variation analysis were entered into
DAVID [13] and KEGG pathways enriched with Benjamini-
Hochberg score of less than 0.25 were selected.
Supporting Information
Table S1 Primers used for qPCR validation of CNVs.
Primers including controls, their product coordinates on hg19 and
their sequence are provided.
(XLSX)
Table S2 Quantitative-PCR validation results of CNVs.
11 regions in 5 genes were used to determine copy number in
regions identified by arrays as deviating from 2 copies. Non-
concordant results are highlighted in red.
(XLSX)
Table S3 Primary ovarian tumor copy number varia-
tion regions identified in 9 patients. Segments of variation
including chromosomal location, which patients are amplified and
deleted, and genes within the region are listed.
(XLSX)
Table S4 Peritoneal metastasis tumor copy number
variation regions identified in 9 patients. Segments of
variation including chromosomal location, which patients are
amplified and deleted, and genes within the region are listed.
(XLSX)
Table S5 Genes identified in copy number variation
regions both shared by primary and metastatic tumors
and those specific to each tumor type. Both official gene
symbols and Refseq IDs are provided. Comparisons include using
a HapMap provided baseline (normal) or comparing the
Peritoneal metastasis to the primary tumor baseline (Peri V
Primary).
(XLSX)
Table S6 Cytokine-Cytokine Receptor gene Copy Num-
ber Variations. Cytokine/Receptor genes were noted for
presence in CNVs for all tumor comparisons conducted.
Amplifications are colored in red and deletions in blue. The CC
subfamily is especially deleted in primary but not metastatic
tumors.
(XLSX)
Table S7 Peritoneal metastasis tumor copy number
variation regions when compared to matched primary
ovarian tumors identified in 9 patients. Segments of
variation including chromosomal location, which patients are
amplified and deleted, and genes within the region are listed.
(XLSX)
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